ConductScience.org, home

Comparison · NCT04252625-sae

Arm 1: Q-Urol vs Arm 2: Placebo: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Arm 1: Q-Urol vs Arm 2: Placebo: serious adverse events. Trial comparisons, record NCT04252625-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04252625-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.434wilson
Risk in group 2000.434wilson
Risk difference, group 1 minus group 20-0.4340.434newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harmfrom the risk difference intervalthe two groups' risks are equal

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Arm 1: Q-Urol
Patients were randomized in a 1:1 ratio to receive Q-Urol, two capsules, twice daily for 6 weeks after brachytherapy placement.~Questionnaires were administered pre- and post-treatment to assess the change in prostatitis symptoms and quality of life measures. The mean values between groups were compared.~Q-Urol: Q-Urol is an over-the-counter herbal supplement manufactured by Farr Laboratories. It is a combination product composed of quercetin, pollen extract, bromelain, and papain.
05EG000
Group 2Arm 2: Placebo
Patients were randomized in a 1:1 ratio to receive Placebo, two capsules, twice daily for 6 weeks after brachytherapy placement.~Questionnaires were administered pre- and post-treatment to assess the change in prostatitis symptoms and quality of life measures. The mean values between groups were compared.~Placebo: placebo capsule
05EG001

Harm

What it counts
Total, serious adverse events
Time frame
The collection of adverse events, serious adverse event, and survival began after the study drug was started and ended 30 days after the last dose study drug (or until new cancer treatment was initiated), up to 13 weeks after treatment initiation.

Source ClinicalTrials.gov

Trial

Title
Trial of Quercetin, Bromelain, Rye Flower Pollen & Papain on Reducing Severity of Radiation-Induced Prostatitis
NCT number
NCT04252625
Phases
PHASE2
Conditions
Prostate Adenocarcinoma
Interventions
Q-Urol, Placebo
Lead sponsor
University of Utah
Results first posted
2025-05-06

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04252625-sae